Eupraxia Pharmaceuticals (EPRX) Long-Term Debt Repayments (2023 - 2024)
Eupraxia Pharmaceuticals' (EPRX) quarterly Long-Term Debt Repayments came in at $18.1 million in Q4 2024, up 496.28% on a QoQ basis from -$4.6 million in Q3 2024.
Eupraxia Pharmaceuticals (EPRX) Long-Term Debt Repayments (2023 - 2024) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 2 years of Long-Term Debt Repayments data on file, last reported at $18.1 million in Q4 2024.
- On a quarterly basis, Long-Term Debt Repayments changed N/A year-over-year to $18.1 million in Q4 2024; TTM through Dec 2024 was $9.1 million, a N/A change from a year earlier, with the FY2024 full-year figure at $9.1 million, changed N/A from the prior year.
- Long-Term Debt Repayments for Q4 2024 stood at $18.1 million, up from -$4.6 million in the prior quarter.
- Over the last five years, Long-Term Debt Repayments for EPRX reached as high as $18.1 million in Q4 2024 and fell as low as -$4.6 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.64 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Eupraxia Pharmaceuticals | 357.29 Mn | 355.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 18.15 Mn |
| Dec 31, 2024 | 18.15 Mn |
| Sep 30, 2024 | -4.58 Mn |
| Sep 30, 2024 | -4.58 Mn |
| Jun 30, 2024 | -4.47 Mn |
| Jun 30, 2024 | -4.47 Mn |
| Mar 31, 2024 | -20,547.00 |
| Mar 31, 2024 | -20,547.00 |
| Sep 30, 2023 | -19,992.00 |
| Sep 30, 2023 | -19,992.00 |
| Jun 30, 2023 | -19,751.00 |
| Jun 30, 2023 | -19,751.00 |
| Mar 31, 2023 | -19,400.00 |
| Mar 31, 2023 | -19,400.00 |